{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"85"},{"groupId":"OG001","value":"75"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"28"}],"units":"Participants"}],"description":"Retention is defined as the percentage of participants who complete the 4 week post-RT questionnaires.","groups":[{"description":"Patients receive oral armodafinil once daily beginning no later than the fifth fraction of brain radiotherapy and continuing for 9-11 weeks in the absence of unacceptable toxicity.\n\nArmodafinil: Given orally","id":"OG000","title":"Arm I - Armodafinil"},{"description":"Patients receive oral placebo once daily beginning no later than the fifth fraction of brain radiotherapy and continuing for 9-11 weeks in the absence of unacceptable toxicity.\n\nplacebo: Given orally","id":"OG001","title":"Arm II - Placebo"}],"paramType":"NUMBER","populationDescription":"All randomized participants","reportingStatus":"POSTED","timeFrame":"4 weeks post-RT (approximately 3 months post randomization)","title":"Retention","type":"PRIMARY","unitOfMeasure":"percentage of participants"}